Nalaganje...
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
A reduction in BCR-ABL1/ABL1(IS) transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients. In this study, we investigated the reliability of multiple BCR-ABL1 th...
Shranjeno v:
| izdano v: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6539817/ https://ncbi.nlm.nih.gov/pubmed/31064152 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20092226 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|